Brian Bressler

University of British Columbia

Papers

1

Total Citations

13

H-Index

1

About

Brian Bressler is a leading translational researcher at the intersection of mass spectrometry and clinical pharmacology. His primary research focus is the development of high-throughput, automated blood tests for the therapeutic drug monitoring (TDM) of biologic therapies, particularly monoclonal antibodies used in treating chronic immune-mediated diseases. His most impactful work, an automated mass spectrometric blood test for infliximab (2019, 13 citations), directly addresses a critical clinical need: optimizing dosing for patients with conditions like Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. By enabling precise, real-time measurement of drug levels, Bressler’s innovations empower clinicians to personalize therapy, improve efficacy, and reduce adverse effects. This work bridges the gap between advanced analytical chemistry and routine patient care, offering a practical solution to a long-standing challenge in precision medicine. Bressler’s contributions are foundational to the emerging field of clinical mass spectrometry, demonstrating how cutting-edge instrumentation can be translated into actionable, cost-effective diagnostics that directly improve outcomes for patients on complex biologic regimens.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab
13 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 2
🏛 Institutions: University of British Columbia

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago